Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)

MYRIAD GENETICS INC

CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.
Mark S. Verratti promoted to COO effective April 30, succeeding Raha.
Q4 2024 revenue $211M (+7% YoY); full-year revenue $838M (+11% YoY). GAAP net loss $43M (Q4) and $127M (FY).
Adjusted EBITDA Q4 $11M, FY $40M; 2025 guidance reaffirmed: revenue $840-$860M, adjusted EPS $0.07-$0.11.
Exclusive license of PATHOMIQ AI platform for prostate cancer; commercial launch planned later in 2025.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Samraat S. Raha

President and Chief Executive Officer

MYGN · MYRIAD GENETICS INC

Effective: 2025-04-30
Filed: February 24, 2025, 6:59 PM ET

the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.

Appointed

Samraat S. Raha

Director

MYGN · MYRIAD GENETICS INC

Effective: 2025-04-30
Filed: February 24, 2025, 6:59 PM ET

the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.

Departed

Paul J. Diaz

President and Chief Executive Officer

MYGN · MYRIAD GENETICS INC

Effective: 2025-04-30
Successor: Samraat S. Raha
Filed: February 24, 2025, 6:59 PM ET

Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samraat S. Raha was appointed as President and Chief Executive Officer at MYRIAD GENETICS INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Samraat S. Raha was appointed as Director at MYRIAD GENETICS INC.

Action: appointed
Role: Director

Exact text from the filing

the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul J. Diaz departed as President and Chief Executive Officer at MYRIAD GENETICS INC.

Action: stepped down
Role: President and Chief Executive Officer

Exact text from the filing

Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025

View on SEC.gov

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-25-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.